Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Melanoma.
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2012
At a glance
- Drugs Axitinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 15 Aug 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 19 Dec 2007 The expected completion date for this trial is now 1 Mar 2008.
- 01 Sep 2006 Status change